Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular o
Journal article published in 2014 by
N. R. Hill,
D. Lasserson,
B. Thompson 
,
R. Perera-Salazar,
J. Wolstenholme,
P. Bower,
T. Blakeman,
D. Fitzmaurice,
P. Little,
G. Feder,
N. Qureshi,
M. Taal,
J. Townend,
C. Ferro,
R. McManus
and other authors.
,
R. Perera-Salazar,
J. Wolstenholme,
P. Bower,
T. Blakeman,
D. Fitzmaurice,
P. Little,
G. Feder,
N. Qureshi,
M. Taal,
J. Townend,
C. Ferro,
R. McManus
and other authors.
